Cohance Lifesciences to Review September Quarter Results on Nov 6

Cohance Lifesciences Limited will consider unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, at its November 6 board meeting, following a June-quarter sales decline of 23.13% year on year to ₹422.26 crore and a net loss of ₹24.12 crore.

When will Cohance Lifesciences announce its September-quarter results?

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, has scheduled a meeting of its Board of Directors for Friday, November 6, 2026. The board will consider and approve unaudited financial results on both a standalone and consolidated basis for the quarter and half-year ended September 30, 2026.

The announcement places the company among listed businesses reporting performance for the second quarter of FY27. The results will provide the next reported financial update after Cohance Lifesciences posted a consolidated loss in the quarter ended June 2026. The company is listed on the BSE under code 543064 and on the NSE under the symbol COHANCE.

The result announcement is also relevant because it covers six months of operations through September 2026. Investors will be able to compare the reported quarter and half-year figures with the June-quarter performance disclosed by the company, although the available information does not provide estimates or guidance for the September period.

Cohance Lifesciences had consolidated its contract development and manufacturing organisation capabilities under the Cohance Lifesciences brand in 2025. Its reported market capitalisation was ₹17,307 crore and the cited current share price was ₹452.

What did Cohance Lifesciences report in the June 2026 quarter?

Cohance Lifesciences reported a consolidated net loss of ₹24.12 crore for the quarter ended June 2026, compared with a consolidated net profit of ₹48.88 crore in the quarter ended June 2025. Sales declined 23.13% year on year to ₹422.26 crore from ₹549.31 crore.

The movement from profit to loss and the reduction in sales make the September-quarter release important for shareholders assessing the company’s reported financial trend. The source material does not specify the reasons for the year-on-year sales decline or the quarterly loss, so the November 6 filing will be the next formal disclosure covering the subsequent period.

The company’s financial update will cover standalone as well as consolidated numbers. Standalone statements reflect the reporting entity, while consolidated statements include the group’s financial position and performance. The company has specifically stated that both sets of unaudited results will be considered by the board.

Why are trading-window and regulatory disclosures relevant?

Cohance Lifesciences has closed its trading window for designated persons and their immediate relatives in connection with the September-quarter results. The company said the window would remain closed from October 1, 2026, until 48 hours after declaration of the unaudited results, in line with applicable SEBI requirements.

A separate disclosure stated that the trading window would remain closed until November 9, 2026, following a closure initiated on September 28, 2026. These disclosures are intended to restrict trading by covered persons while unpublished price-sensitive information related to financial results is being handled.

The company also submitted confirmation certificates issued by KFin Technologies Limited, its Registrar and Share Transfer Agent, for the quarter ended September 30, 2026. The filing was made with BSE and NSE in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Corporate governance changes have also been disclosed during the period. Cohance Lifesciences announced the appointment of Abhimanyu Ojha as Chief Financial Officer on October 12, 2026. This followed the resignation of Himanshu Agarwal as Executive Director and Chief Financial Officer with effect from September 13, 2026. The company’s eighth annual general meeting was held on September 17, 2026.

What regulatory matters are investors tracking at Cohance Lifesciences?

Cohance Lifesciences has disclosed a Form 483 containing five observations from the US Food and Drug Administration at its Jaggaiahpet, Andhra Pradesh API manufacturing facility. The inspection took place from September 14 to September 19, according to the company’s stock exchange filing. Details of the observations were not disclosed.

The company stated that it had initiated corrective and preventive actions and would submit its response within the stipulated timeline. A Form 483 records inspectional observations and is separate from a final regulatory determination. The available disclosure does not state the date of the company’s response or the FDA’s subsequent assessment.

Separately, the FDA issued a warning letter dated January 30, 2026, relating to a Cohance Lifesciences facility at IDA Nacharam in Telangana, identified by FEI 3008768274. The letter described significant current good manufacturing practice violations for finished pharmaceuticals following an inspection conducted from August 4 to August 12, 2025.

The FDA acknowledged the company’s commitment to temporarily suspend manufacturing and release of drug products from that facility from August 16, 2025. It asked the company to clarify when it intended to resume manufacturing drugs for the US market and said it must notify the agency before restarting operations regulated under the Federal Food, Drug, and Cosmetic Act.

Conclusion

The November 6 board meeting is the immediate reporting event for Cohance Lifesciences after sales fell to ₹422.26 crore and the company recorded a ₹24.12 crore consolidated loss in the June 2026 quarter. The outcome will matter for investors tracking reported financial performance, group-level results, governance disclosures, and the company’s regulatory compliance matters.

The next confirmed milestone is the board’s consideration of unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. Investors will also watch for any further company disclosures on corrective actions at the Jaggaiahpet API facility and remediation related to the FDA warning letter for the Nacharam facility.